SCHEMBL2460148

SCHEMBL2460148

NCc1cccc(C2=C3C=NC=C[N+]3(N)C(c3cccc(OCc4ccccc4)c3)=N2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.42
MAOB P27338 4/20 0.38
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
PRKDC P78527 1/20 0.36
IGF1R P08069 2/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
NR1H2 P55055 1/20 0.35
NR4A2 P43354 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
BACE1 P56817 1/20 0.35
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
F11 P03951 1/20 0.34
KLKB1 P03952 1/20 0.34
F7 P08709 1/20 0.34
TPSB2 P20231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460398 0.93 MAOB (0.41) MAOBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2459704 0.91 TSHR (0.39) CFDMAOBPIK3CDPIK3CAPIK3CB
SCHEMBL2462894 0.89 ALOX5 (0.41) MAOBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2459477 0.86 MRGPRX4 (0.43) MAOBNR4A2MRGPRX4SPHK2
SCHEMBL2460200 0.85 MAOB (0.37) MAOBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2456898 0.85 NOS1 (0.35) CFDMAOBNOS1NOS2NR4A2
SCHEMBL2462756 0.85 GRM5 (0.41) PRKDCIGF1R
SCHEMBL2460199 0.84 PARP10 (0.45) MAOBNR4A2MRGPRX4SPHK2
SCHEMBL2465920 0.84 BACE1 (0.39) MAOBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3537072 0.84 MAOB (0.40) MAOBPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 CFD 4850/4885MAOB 1546/4885PIK3CD 636/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 CFD 4850/4885MAOB 1546/4885PIK3CD 636/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 CFD 4850/4885MAOB 1546/4885PIK3CD 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.